qrxpharma

A new solution for doctors and painkillers

John Kimber
John Kimber
Independent Investment Research

QRXPharma just saw its market cap shrink 75% from $120mil to $30mil on the FDA saying 'no', as Matthijs smith warned Livewire yesterday: There is unlikely to...

Livewire Equities
Livewire Equities
Livewire

There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session with the FDA's Advisory...

Matthijs Smith
Matthijs Smith
Canaccord Genuity Australia